Roche and Spark Therapeutics announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for US$114.50 per Share.
Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2019, by and among Roche Holdings and Spark, the Offer, which was previously scheduled to expire at 5:00 p.m., New York City time, on Tuesday, December 10, 2019, has been extended until 5:00 p.m., New York City time, on Monday, December 16, 2019.
The Offer was extended to provide additional time for the US Federal Trade Commission (FTC) and the UK Competition and Markets Authority (CMA) to complete their previously disclosed reviews of Roche’s pending acquisition of Spark. The parties remain committed to the transaction and are working cooperatively and expeditiously with the FTC and the CMA.
Full Content: Market Watch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.